A phase 2 trial has demonstrated the promising efficacy and tolerability of neoadjuvant gemcitabine plus split-dose cisplatin in patients with localised high-grade upper tract urothelial carcinoma.

Roberto Iacovelli presents the ARIES trial of frontline avelumab in patients with PD-L1-positive advanced urothelial cancer who are unable to tolerate cisplatin. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Peter O’Donnell gives an update on the KEYNOTE-052 trial findings for first-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Phase 2 trial findings demonstrate potential for the first-line use of rogaratinib plus atezolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma with FGFR1–3 mRNA overexpression or FGFR3 mutations. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Matthew Galsky shares exploratory data from the IMvigor130 trial suggesting the benefit of atezolizumab monotherapy in certain cisplatin-ineligible patients with advanced urothelial carcinoma. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Arjun Balar reports on EV-201 results suggesting that cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer may benefit from treatment with enfortumab vedotin after checkpoint inhibitor therapy (4:14).

Enfortumab vedotin may provide a platinum-free option for patients who have received prior immune checkpoint inhibitor therapy for advanced urothelial carcinoma and are unable to tolerate cisplatin, suggest phase 2 trial findings.

Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.

The administration of sodium thiosulfate after cisplatin reduces the incidence of hearing loss in children with standard-risk hepatoblastoma, according to an international, randomized trial.

“[T]he results confirm that first-line pembrolizumab elicits clinically meaningful, durable antitumor activity in cisplatin-ineligible patients with advanced urothelial cancer,” the presenter said.

Treatment with the antioxidant sodium thiosulfate can reduce the incidence of platinum-induced hearing loss in children and adolescents with cancer treated with cisplatin, research suggests.

The phase 3 trial, which was simultaneously published in The New England Journal of Medicine , assessed the impact of adding four 3-week cycles of pembrolizumab 200 mg to standard neoadjuvant cisplatin-based chemotherapy, as well as 13 weeks of adjuvant pembrolizumab 200 mg instead of placebo.

Post-hoc analysis in ESMO Open  in 2021 pointed to an atezolizumab OS benefit among SAUL participants who had previously received cisplatin or carboplatin, and identified prognostic markers for OS with second-line atezolizumab, including Bellmunt risk and PD-L1 expression.

Use of veliparib during cisplatin chemotherapy may help improve progression-free survival in patients with metastatic triple-negative breast cancer displaying biomarker characteristics similar to those seen in BRCA1/2 mutation-positive disease, suggest findings from a phase 2 trial.

The team explains that bladder-preserving trimodality therapy with transurethral bladder tumor resection and cisplatin-based chemoradiotherapy “can be an effective alternative to radical cystectomy” for MIBC, “but biomarkers are needed to guide optimal patient selection.”

The latest findings from the EV-103 study add support for the first-line use of enfortumab vedotin plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

“All patients who relapsed were successfully treated with salvage standard-dose cisplatin-based chemotherapy,” report Papachristofilou and co-authors.

The CHOICE-01 trial enrolled 465 individuals with treatment-naïve locally advanced or metastatic NSCLC lacking EGFR or ALK alterations and randomly assigned them to receive intravenous toripalimab 240 mg or placebo every 3 weeks alongside four to six cycles of chemotherapy, consisting of nab-paclitaxel plus carboplatin for squamous disease and pemetrexed plus cisplatin or carboplatin for nonsquamous disease.

Over half (57.6%) of the participants had received carboplatin plus gemcitabine chemotherapy, while 31.8% had received cisplatin plus gemcitabine, and 10.6% had received another regimen.